Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.
Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.
复制标题
DOI：
10.1016/j.jaad.2021.03.094
复制
发表时间：
2022-03
影响因子：
13.8
通讯作者：
Semenov, Yevgeniy R.
中科院分区：
文献类型：
--
作者：
Wongvibulsin, Shannon;Pahalyants, Vartan;Kalinich, Mark;Murphy, William;Yu, Kun-Hsing;Wang, Feicheng;Chen, Steven T.;Reynolds, Kerry;Kwatra, Shawn G.;Semenov, Yevgeniy R.
关键词：
在越来越多接受免疫检查点抑制剂（ICI）治疗的患者中报告了各种皮肤病，但目前对皮肤免疫相关不良事件（irAE）的了解有限。确定ICI开始后皮肤irAE的累积发生率、分布和风险因素。这是一项对国家保险索赔数据库中的患者进行的回顾性队列研究，包括接受ICI治疗的癌症患者和匹配的对照组。该研究包括8637名ICI患者和8637名匹配的对照。皮肤irAE的总体发生率为25.1%，中位发生时间为113天。ICI组瘙痒、粘膜炎、红皮病、斑丘疹、白癜风、扁平苔藓、大疱性类天疱疮、Grover病、皮疹、其他非特异性皮疹和药疹或其他非特异性药物反应的发生率显著较高。黑色素瘤和肾细胞癌患者以及接受联合治疗的患者发生皮肤irAE的风险较高。回顾性设计，无法访问患者病历数据。本研究确定了真实临床环境中的皮肤irAE，并强调了风险特别高的患者群体。这些结果可以帮助皮肤科医生在床边诊断皮肤irAE，并制定管理建议，以参考肿瘤学家关于继续ICI治疗。
A variety of dermatoses have been reported in the growing number of patients treated with immune-checkpoint inhibitors (ICIs), but the current understanding of cutaneous immune-related adverse events (irAEs) is limited. To determine the cumulative incidence, distribution, and risk factors of cutaneous irAEs after ICI initiation. This was a retrospective cohort study of patients in a national insurance claims database including cancer patients treated with ICIs and matched controls. The study included 8637 ICI patients and 8637 matched controls. The overall incidence of cutaneous irAEs was 25.1%, with a median onset time of 113 days. The ICI group had a significantly higher incidence of pruritus, mucositis, erythroderma, maculopapular eruption, vitiligo, lichen planus, bullous pemphigoid, Grover disease, rash, other nonspecific eruptions, and drug eruption or other nonspecific drug reaction. Patients with melanoma and renal cell carcinoma and those receiving combination therapy were at a higher risk of cutaneous irAEs. Retrospective design without access to patient chart data. This study identifies cutaneous irAEs in a real-world clinical setting and highlights patient groups that are particularly at risk. The results can aid dermatologists at the bedside in the diagnosis of cutaneous irAEs and in formulating management recommendations to referring oncologists regarding the continuation of ICI therapy.
登录
查看更多内容
PD-1和PD-L1抑制剂作为癌症免疫疗法的一种形式的开发：对注册试验和未来考虑的全面综述。
影响因子：
10.9
作者：
Gong J;Chehrazi-Raffle A;Reddi S;Salgia R
通讯作者：
Salgia R
DOI：
10.1056/nejmoa1504030
发表时间：
2015-07-02
期刊：
The New England journal of medicine
影响因子：
--
作者：
Larkin J;Chiarion-Sileni V;Gonzalez R;Grob JJ;Cowey CL;Lao CD;Schadendorf D;Dummer R;Smylie M;Rutkowski P;Ferrucci PF;Hill A;Wagstaff J;Carlino MS;Haanen JB;Maio M;Marquez-Rodas I;McArthur GA;Ascierto PA;Long GV;Callahan MK;Postow MA;Grossmann K;Sznol M;Dreno B;Bastholt L;Yang A;Rollin LM;Horak C;Hodi FS;Wolchok JD
通讯作者：
Wolchok JD
影响因子：
13.8
作者：
Geisler AN;Phillips GS;Barrios DM;Wu J;Leung DYM;Moy AP;Kern JA;Lacouture ME
通讯作者：
Lacouture ME
影响因子：
1.7
作者：
Silva, Josenilson Antônio da;Mesquita, Kleyton de Carvalho;Campbell, Iphis Tenfuss
通讯作者：
Campbell, Iphis Tenfuss
DOI：
10.1097/pas.0000000000000900
发表时间：
2017-10
期刊：
The American journal of surgical pathology
影响因子：
--
作者：
Kaunitz GJ;Loss M;Rizvi H;Ravi S;Cuda JD;Bleich KB;Esandrio J;Sander I;Le DT;Diaz LA Jr;Brahmer JR;Drake CG;Hollmann TJ;Lacouture ME;Hellmann MD;Lipson EJ;Taube JM
通讯作者：
Taube JM